LA JOLLA, Calif., Jan. 31 /PRNewswire-FirstCall/ -- Stephen D. Ferrone, CEO and President of Immunosyn Corporation (OTC Bulletin Board: IMYN) has been featured in an exclusive interview with CEOCFO Interviews & News. The interview is posted on http://www.immunosyn.com/news-conferences.html
The interview covers topics including Immunosyn's immediate focus, its future development and its market potential, the shift in the pharmaceutical industry toward biologically-derived drugs, the science behind SF-1019, the role of Argyll Biotechnologies, LLC its strategic partner and largest shareholder, Immunosyn's financial picture, the US and European regulatory approval process as it pertains to SF-1019 trials and milestones for which the public and investors should watch.
"We are pleased to be included with CEOCFO's esteemed collection of companies. This interview offers us the opportunity to present noteworthy announcements to brokers, institutional managers and individual investors as part of our strategic market communication plan," says Stephen D. Ferrone.
About CEOCFO Interviews & News http://ceocfointerviews.com:
CEOCFO Interviews & News is a bi-weekly print online publication, marketing engine featuring publicly traded & venture capital companies on the U.S. (NYSE, NASDAQ, AMEX, OTC: BB, Pink Sheets) and Canadian (TSX & TSX-V) stock exchanges, Investment & Money Management Ideas.
About Immunosyn Corporation
La Jolla, CA-headquartered Immunosyn Corporation (IMYN.OTC.BB) plans to
market and distribute life enhancing therapeutics. Currently, the company
has exclusive worldwide rights from its largest shareholder, Argyll
Biotechnologies, LLC, to market, sell and distribute SF-1019, a compound
that was developed from extensive research into Biological Response
Modifiers (BRMs). Argyll Biotechnolo
|SOURCE Immunosyn Corporation|
Copyright©2008 PR Newswire.
All rights reserved